Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study

Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY studyIntroduction: Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty. Aim: To assess the efficacy and tolerability of flibanserin, a postsynaptic 5-HT1A agonist/5-HT2A antagonist, in the treatment of premenopausal women with…

Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial

Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trialObjective: This study aimed to assess the efficacy and safety of flibanserin, a serotonin receptor 1A agonist/serotonin receptor 2A antagonist, in postmenopausal women with hypoactive sexual desire disorder (HSDD). Methods: Naturally postmenopausal women with HSDD received flibanserin 100…

Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial

Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trialIntroduction: Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty. Aim: The aim of this study was to assess the efficacy and safety of the 5-HT1A agonist/5-HT2A antagonist flibanserin in premenopausal women…